Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VVD-159642 + sotorasib
- Development stage
- Unknown
- Lead developer
- Vividion Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VVD-159642 + sotorasib is an oral combination therapy under investigation for the treatment of advanced solid tumors driven by RAS mutations. VVD-159642 is a small molecule inhibitor that selectively blocks activation of the PI3K-alpha pathway by RAS proteins, aiming to inhibit oncogenic signaling crucial to solid tumor growth without affecting normal cellular function. Sotorasib is a small molecule targeting KRAS G12C, covalently inhibiting mutant KRAS, and is approved as a targeted therapy for specific cancers. This combination is being tested to determine safety, pharmacodynamics, pharmacokinetics, and preliminary anti-tumor activity, based on preclinical rationale that dual targeting of RAS-driven and MAPK pathways may increase efficacy or overcome resistance seen with single agents. Both agents are administered orally.
- Other names
- AMG 510AMG510AMG-510
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)RAS–Phosphoinositide 3-kinase alpha interface (RAS–PI3Kα interface)
Beyond the preview
Go deeper on VVD-159642 + sotorasib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VVD-159642 + sotorasib.